Natalia Rodón¹, Ruth Román¹, Montse Verdú^1,3, Miquel Calvo⁴, Beatriz García-Peláez¹, Marta González¹, Carme Pubill³ y Xavier Puig^1,2,3.

¹BIOPAT. Biopatologia Molecular, SL, Grup Assistència; ²Hospital de Barcelona-SCIAS, Grup Assistència; ³Histopat Laboratoris; ⁴Departament d’Estadística, Universitat de Barcelona. Barcelona

Background:

KRAS mutations, present in approximately 30-50% of colorectal carcinomas (CRC) has been recently associated with lack of response to anti-EGFR therapy, poor prognosis and high mitotic activity. Nevertheless, its relation to other histopathological and molecular parameters has not been well established.

Our first approach was to determine […]

R ROMAN¹, M VERDU^1,3, A VIDAL^3,5, M CALVO⁴, X SANJUAN⁵, M JIMENO⁶, A SALAS⁷, J AUTONELL⁸, I TRIAS⁹, N RODON¹, M GONZALEZ¹, B GARCIA¹ and X PUIG^1,2,3.

¹BIOPAT.Biopatologia Molecular, Barcelona, Spain; ²Hospital de Barcelona, Barcelona, Spain; ³Histopat Laboratoris, Barcelona, Spain; ⁴Statistics Department, Universitat de Barcelona, Barcelona, Spain; ⁵Hospital Universitari de Bellvitge, Barcelona, Spain; ⁶Hospital del Mar, Barcelona, Spain; ⁷Hospital Mútua de Terrassa, Terrasa, Spain; ⁸Hospital General de Vic, Vic, Spain and ⁹Hospital Plató, Barcelona, Spain.

Background: High microsatellite instability (MSI-H) allows the […]

Ruth Roman¹, Montse Verdú ^1,3, August Vidal ^1,3, Miquel Calvo ⁴, Natalia Rodón¹, Beatriz García¹, Marta González¹ and Xavier Puig^1,2,3.

¹BIOPAT. Biopatologia Molecular, SL, Grup Assistencia; ²Hospital de Barcelona SCIAS, Grup Assistència; ³Histopat Laboratoris and ⁴Statistics Department, Universitat de Barcelona. Barcelona, Spain.

INTRODUCTION: Invasive micropapillary carcinoma (MC) is associated with frequent lymph node metastasis and adverse clinical outcome. It has been reported in ovary, breast, urinary bladder, ureter, lung, parotid gland and, recently, in colon. Little is known about the morphological and […]

Roman R,¹ Colomer A,¹ Erill N,¹ Verdú M,² Ibáñez R,¹ Cordon-Cardo C,¹ Puig X.^1,2

¹BIOPAT. Biopatologia Molecular, Grup Assistència & ²HISTOPAT Laboratoris, Barcelona, Catalonia, Spain.

Background: Irinotecan (CPT-11) is currently used as first- or second-line treatment for colorectal cancer, either alone or in combination with 5-fluorouracil based regimens. UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzes the inactivation of SN-38, the active metabolite of irinotecan, through glucuronidation. UGT1A1*28, a polymorphic variant of this enzyme displaying an additional TA dinucleotide in the promoter TATA box, has been […]